|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | St. Vincent's Medical Center |
|---|---|
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002065 |
Purpose
To assess the safety and efficacy of depot disulfiram as a new treatment for AIDS and AIDS related complex.
| Condition | Intervention |
|---|---|
|
HIV Infections |
Drug: Disulfiram |
| Study Type: | Interventional |
| Study Design: | Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Depot Disulfiram for AIDS and ARC |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have a positive diagnosis of AIDS or AIDS related complex (ARC) according to the CDC criteria.
Patients must be free of clinically significant organic disease affecting neurologic, hepatic, renal, and clinical status.
Patients must be free of clinically significant organic disease affecting neurologic, hepatic, renal, and clinical status.
History of alcohol abuse.
Contacts and Locations
More Information
| ClinicalTrials.gov Identifier: | NCT00002065 History of Changes |
| Other Study ID Numbers: | 024A |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Food and Drug Administration |
|
Delayed-Action Preparations Disulfiram Acquired Immunodeficiency Syndrome AIDS-Related Complex |
|
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes |
Immune System Diseases Slow Virus Diseases Disulfiram Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Alcohol Deterrents Central Nervous System Agents Therapeutic Uses |